Lauren White
Net worth: 121 909 $ as of 31/05/2026
Net worth: 121 909 $ as of 31/05/2026
Lauren A. White is currently Chief Financial Officer at Seaport Therapeutics, Inc. since 2024.
Former roles include Chief Financial Officer & Senior Vice President at ImmunoGen, Inc. from 2023 to 2024, Treasurer, Chief Financial & Accounting Officer at C4 Therapeutics, Inc. from 2021 to 2023, and VP, Global Head-Business Planning & Analysis at Novartis Institutes for Biomedical Research, Inc. Education includes an MBA from Harvard Business School conferred in 2007 and an undergraduate degree from Wallace E Carroll School of Management conferred in 2000.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
0.01% | 04/05/2026 | 6,702 ( 0.01% ) | 121 909 $ | 31/05/2026 |
| Companies | Position | Start |
|---|
| Companies | Position | End |
|---|---|---|
| IMMUNOGEN, INC. | Director of Finance/CFO | 01/01/2024 |
| C4 THERAPEUTICS, INC. | Director of Finance/CFO | 15/09/2023 |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Corporate Officer/Principal | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
ImmunoGen, Inc.
ImmunoGen, Inc. BiotechnologyHealth Technology Develops anticancer therapeutics | Health Technology |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Commercial Services |
Harvard Business School
Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Wallace E Carroll School of Management
Wallace E Carroll School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
C4 Therapeutics, Inc.
C4 Therapeutics, Inc. BiotechnologyHealth Technology Develops targeted protein degradation therapeutics for the treatment of cancer | Health Technology |
Select your edition
All financial news and data tailored to specific country editions